微生物特征可以预测重症肺炎的短期预后
Shen-Shen Huang1, Jia-Yong Qiu1,2, Shuang-Ping Li1
1Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Frontiers in cellular and infection microbiology
|August 19, 2024
概括
肺部微生物群的组成会影响严重肺炎的预后. 特定的细菌如Acinetobacter baumannii和Klebsiella pneumoniae与更高的死亡率有关,而其他细菌可能表明生存率.
科学领域:
- 微生物学 微生物学
- 肺部病理学 肺部病理学
- 传染性疾病 传染性疾病
背景情况:
- 严重的肺炎是全球死亡的主要原因.
- 肺微生物群在严重肺炎病原和预后中的作用仍然不完全理解.
- 甲基因组下一代测序 (mNGS) 为分析呼吸道感染中的微生物群体提供了强大的工具.
研究的目的:
- 研究重症肺炎患者肺部微生物群的组成和多样性.
- 探索肺部微生物群与短期预后 (28天死亡率) 之间的关联.
- 为了确定预测严重肺炎死亡率的关键微生物标志物.
主要方法:
- 对236名严重肺炎患者进行了回顾性队列研究.
- 使用元基因组下一代测序 (mNGS) 分析的支气管洗液.
- 分析包括alpha/beta多样性,LEfSe,机器学习和网络并发分析.
主要成果:
- 28天的死亡率为37.7%. 没有幸存者具有更高的并发症和严重性得分.
- 虽然总体的α/β多样性没有显著差异,但特定的细菌丰度有所不同:Acinetobacter baumannii,Klebsiella pneumoniae和Enterococcus faecium在未幸存者中较高.
- 机器学习确定了16种关键细菌,包括Klebsiella pneumoniae,作为短期死亡率的预测因素;网络分析显示,非幸存者的复杂性更大.
结论:
- 肺部微生物群的组成是严重肺炎短期预后的潜在预测因素.
- 显著的微生物形状和相互作用模式与生存和不生存有关.
- 需要进一步的研究来了解这些微生物差异的临床影响和机制.
更多相关视频
相关概念视频
01:30Pneumonia I: Introduction
215
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
215
01:30Pneumonia III: Complications and Assessment
193
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
193
01:29Pneumonia II: Pathophysiology
237
The pathophysiology of pneumonia involves the following steps:
237
01:28Pneumonia IV: Management
313
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
313